April 29 (Reuters) -

U.S. drugmaker Pfizer ( PFE ) reported first-quarter profit

above Wall Street estimates on Tuesday, helped by cots cuts and

better-than-expected sales of its heart disease drug, Vyndaqel.

On an adjusted basis, Pfizer ( PFE ) earned 92 cents per share in

the latest quarter, compared with analysts' expectations of 66

cents per share, according to LSEG data.

Investors are closely watching for any potential impact on

Pfizer's ( PFE ) vaccine business and any changes to recommendations for

receiving flu, COVID and other shots under the new health

secretary Robert F Kennedy Jr., a longtime vaccine skeptic.

Pfizer ( PFE ) and other drugmakers are also at risk of proposed

hefty duties on trade partners such as China, which is a key

source of raw ingredients and supplies for the pharmaceutical

and medical device industries.

Shares of the drugmaker, which have fallen 13.1% so far

this year, rose 1% in premarket trading.

It reported total revenue of $13.70 billion for the

first quarter, compared with analysts' expectations of $13.91

billion, according to LSEG data.